SAN DIEGO, Oct. 11, 2026 (GLOBE NEWSWIRE) — First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a clinical-stage biotechnology company advancing antibody therapeutics that modulate immune pathways implicated in autoimmune and inflammatory diseases, will host an investor call and live webcast to review top-line data from Cohort 1, a gluten-challenge study assessing prevention of mucosal damage, of the global Phase 1b trial of investigational ANB033, a CD122 antagonist, in celiac disease on Monday, Oct. 12, 2026, at 8:30am ET/5:30am PT. A live webcast of the call will be available on the First Tracks website at: https://ir.firsttracksbio.com/news-events/events. The data will be provided in a morning press release and presented during the webcast. A replay of the webcast will be available for at least 30 days following the event. About...

– In an independent, propensity score-matched analysis of 2,684 individuals living with ATTR-CM from Epic COSMOS, the largest U.S. electronic health record database, acoramidis was associated with a statistically significant 18% lower risk of a composite of death, all-cause hospitalization, new-onset atrial fibrillation, and diuretic intensification versus tafamidis (HR 0.82; 95% CI 0.73-0.93; p

•    Stellantis offered an exclusive preview of six of the nine concept cars set to debut at the Paris Motor Show, October 12-18  •    Alfa Romeo, Citroën, DS Automobiles, FIAT, Opel and PEUGEOT showcased how creativity and innovation enable emotion, serve people and enhance freedom of choice •    Stellantis Chairman John Elkann, CEO Antonio Filosa andEnlarged Europe COO Emanuele Cappellano highlightedhow FaSTLAne 2030 strategic plan is translating into tangible results, through technologies, products and  innovations with the customer at the center •    Gilles Vidal, Head of Design, Enlarged Europe, presented the concept cars, illustrating how Stellantis is challenging conventions and accelerating towards the future •    “The Night Before” offered a preview of Stellantis’ bold presence at the Paris Motor Show, featuring the exhibition’s...

– Significant performance improvement seen across all subtypes of advanced precancerous lesions, which are important to detect for potential colorectal cancer prevention – – Overall detection of colorectal cancer remained consistent with test’s first version, achieving 80.4% sensitivity at 90% specificity – BRISBANE, Calif., Oct. 11, 2026 (GLOBE NEWSWIRE) — Freenome, Inc. (Nasdaq: FRNM), an early cancer detection company developing blood-based tests, today announced the company will present late-breaking data on an updated version of its SimpleScreen™ CRC blood-based screening test at the American College of Gastroenterology (ACG) 2026 Annual Meeting in Nashville. Freenome conducted a pivotal clinical validation study to assess the performance of assay and algorithm improvements for the updated version of SimpleScreen CRC....

– Encaleret administration increased bone turnover, based on its action to recover endogenous PTH secretion in patients with ADH1 – 100% of participants who received encaleret reported improvements in at least one ADH1 symptom compared to 46% of participants who received standard of care – Improvements in ADH1-related impacts on daily functioning were also more frequently reported with encaleret compared to standard of care – The FDA has accepted BridgeBio’s NDA for encaleret in ADH1 and granted Priority Review, with a PDUFA target action date of May 8, 2027; the Company also submitted an MAA to the EMA – The first participant was dosed in RECLAIM-HP, the registrational Phase 3 study of encaleret in adults and adolescents with chronic hypoparathyroidism PALO ALTO, Calif., Oct. 11, 2026 (GLOBE NEWSWIRE) —...

HANGZHOU, China, Oct. 11, 2026 (GLOBE NEWSWIRE) — Geely Auto Group today announced the market launch of its first electrified off-road SUV, named Zhanjian 700 in China, and the first production model built on its dedicated GTA architecture for electrified off-road vehicles.Positioned as an AI-powered all-terrain SUV, the model combines off-road capability, electrified performance, intelligent vehicle control, safety and a versatile interior for both daily driving and demanding terrain. It addresses a longstanding compromise in the rugged SUV segment: choosing between off-road capability and on-road comfort, or between performance and efficiency. By integrating architecture, powertrain and chassis control as one system, Geely delivers capability without sacrificing everyday usability. A purpose-built foundation for city road and...

In the MEERKAT and SANDCAT studies, vamikibart demonstrated sustained improvements in vision and reductions in macular thickness in patients with UME at 52 weeks1,2 UME is the leading cause of moderate and severe vision loss in patients with uveitis, posing a significant risk of blindness if left untreated3,4 The FDA has accepted Roche’s Biologics License Application (BLA), with an approval decision expected by July 2027Basel, 10 October 2026 – Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today new one-year data from the Phase III MEERKAT and SANDCAT studies evaluating investigational vamikibart compared with a sham procedure that mimics intravitreal (IVT) injections in adults with uveitic macular edema (UME). Across both studies, data continue to support the potential for rapid and sustained improvements in vision and reductions...

SHANGHAI, China, Oct. 10, 2026 (GLOBE NEWSWIRE) — FREELANDER has outlined the global validation programme for FREELANDER 8 ahead of the first test drive of its international variant at the 2026 Chery International User Summit in Wuhu later this month. The programme involved more than 1,000 test vehicles across more than 50 road types worldwide. Key engineering results were presented at the FREELANDER Global Brand Launch, held at Emirates Palace Mandarin Oriental in Abu Dhabi on 29 September 2026. Two FREELANDER 8 vehicles on a gravel track in rocky mountain terrain A Global Validation Programme More than 200 vehicles were dedicated to all-terrain durability testing, covering a combined 2.15 million kilometres. The wider programme covered deserts, gravel roads, rocky terrain, steep inclines, water crossings and paved roads. It also...

WUHU, China, Oct. 10, 2026 (GLOBE NEWSWIRE) — The 2026 Chery International User Summit will take place from October 18 to 24, alongside an exclusive media test drive event featuring Chery Group’s LUXEED models. Leading media representatives and key opinion leaders (KOLs) from the United Arab Emirates, Thailand, and Indonesia will get behind the wheel of LUXEED’s latest global offerings, embarking on an immersive driving experience that spans long-distance highway driving, scenic mountain passes, and a professional proving ground.Bringing together 15 influential media professionals and KOLs from across the region, the event will evaluate LUXEED’s capabilities from diverse perspectives, with a focus on the priorities of global markets. Participants will tackle a 185-kilometer route combining high-speed expressways and winding...

WUHU, China, Oct. 10, 2026 (GLOBE NEWSWIRE) — As the 2026 Chery International User Summit, operated by Chery Group, taking place from October 18 to 24 in Wuhu, China, draws near, LUXEED is set to launch an extensive global media test drive. Bringing together media representatives and key opinion leaders (KOLs) from around the world, the event will offer an immersive journey from urban streets to cloud-wrapped mountain peaks, focusing on real-world intelligent driving capabilities and dynamic vehicle performance.This media test drive will feature a comprehensive blend of real-road driving and professional proving ground evaluations. Departing from Chery International Headquarters, the fleet will navigate urban thoroughfares, expressways and winding mountain highways before arriving at the Guangde Proving Ground. Spanning approximately...